Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: A double-blind, controlled trial in adult patients with non-hodgkin B cell lymphoma

被引:41
作者
Safdar, Amar
Rodriguez, M. Alma
Fayad, Luis E.
Rodriguez, Gilhen H.
Pro, Barbara
Wang, Michael
Romaguera, Jorge E.
Goy, Andre H.
Hagemeister, Fredrick B.
McLaughlin, Peter
Bodey, Gerald P.
Kwak, Larry W.
Raad, Issam I.
Couch, Robert B.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Unit 402, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Virol Mol & Microbiol, Houston, TX 77030 USA
关键词
D O I
10.1086/508493
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In 27 patients randomized to receive commercial trivalent influenza vaccine (TIV) containing 15 mu g of the hemagglutinin (HA) of influenza A (H3N2 and H1N1) and B virus or a recombinant vaccine (rHAO) containing 15, 45, or 135 mg of each HA, reactogenicity was minor. Among patients with similar prevaccination titers, 40% given 45 mg and 60% given 135 mg of rHAO developed an increase in influenza A/H3 neutralizing antibody levels; there were no increases in 4 given TIV. For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135-mu g vaccine.
引用
收藏
页码:1394 / 1397
页数:4
相关论文
共 15 条
  • [1] [Anonymous], DIAGNOSTIC PROCEDURE
  • [2] Couch Robert B., 1997, American Journal of Medicine, V102, P2, DOI 10.1016/S0002-9343(97)00003-X
  • [3] MICRONEUTRALIZATION TEST FOR INFLUENZA-A AND INFLUENZA-B AND PARA-INFLUENZA-1 AND PARAINFLUENZA-2 VIRUSES THAT USES CONTINUOUS CELL-LINES AND FRESH SERUM ENHANCEMENT
    FRANK, AL
    PUCK, J
    HUGHES, BJ
    CATE, TR
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1980, 12 (03) : 426 - 432
  • [4] GROSS PA, 1985, REV INFECT DIS, V7, P613
  • [5] Harper Scott A., 2005, Morbidity and Mortality Weekly Report, V54, P1
  • [6] HARRIS NL, 1994, BLOOD, V84, P1361
  • [7] Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly
    Keitel, WA
    Cate, TR
    Atmar, RL
    Turner, CS
    Nino, D
    Dukes, CM
    Six, HR
    Couch, RB
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1996, 3 (05) : 507 - 510
  • [8] Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study
    Ljungman, P
    Nahi, H
    Linde, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (01) : 96 - 98
  • [9] ANTIBODY-RESPONSE TO A 2-DOSE INFLUENZA VACCINE REGIMEN IN ADULT LYMPHOMA PATIENTS ON CHEMOTHERAPY
    LO, W
    WHIMBEY, E
    ELTING, L
    COUCH, R
    CABANILLAS, F
    BODEY, G
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1993, 12 (10) : 778 - 782
  • [10] INACTIVATED VACCINES .1. VOLUNTEER STUDIES WITH VERY HIGH DOSES OF INFLUENZA VACCINE PURIFIED BY ZONAL ULTRACENTRIFUGATION
    MOSTOW, SR
    SCHOENBAUM, SC
    COLEMAN, MT
    DOWDLE, WR
    KAYE, HS
    [J]. POSTGRADUATE MEDICAL JOURNAL, 1973, 49 (569) : 152 - 158